drugset / Trial / NCT02754141
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tumor-shrinking ability of experimental medication BMS-986179 alone and when combined with Nivolumab, in patients with solid cancers that are advanced or have spread.
Timeline
- Start
- 2016-06-21
- Primary completion
- 2021-10-12
- Completion
- 2021-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986179 | Unknown | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Background | rHuPH20 | Protein / enzyme biologic | — | — |